Real-world assessment of adherence to inclisiran dosing schedule and LDL-C reduction in patients with hypercholesterolemia in Austria
Journal of Clinical Lipidology · 2026-09 · 20 (9) · 1921-1932
DOI: 10.1016/j.jacl.2026.07.025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Lipidology, 2026-09. Verfasst von Dieter Pätzold und 11 weiteren Autor:innen. Beteiligte Einrichtung: Kardiologisch-internistische Ordination, Graz, Austria (Pätzold). Hauptthemen laut MEDLINE: Cholesterol, LDL, Hypercholesterolemia, RNA, Small Interfering. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Pharmaceuticals Corporation.
Abstract (Originalsprache)
BACKGROUND: Inclisiran is a small interfering RNA that safely and effectively lowers low-density lipoprotein cholesterol (LDL-C) with twice-yearly dosing (after the initial and 3-month doses). However, data on real-world inclisiran use are limited. OBJECTIVE: This descriptive, noninterventional, retrospective chart review aimed to assess dosing schedule adherence, patient profiles, and LDL-C change in participants prescribed inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in routine clinical practice in Austria. METHODS: Participants with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk equivalent, or familial hypercholesterolemia, LDL-C ≥70 mg/dL
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kardiologisch-internistische Ordination, Graz, Austria (Pätzold).
- VIVIT Vorarlberg Institute for Vascular Investigation and Treatment am Landeskrankenhaus Feldkirch, Feldkirch, Austria (Vonbank).
- Division of Internal Medicine, Saint John of God Hospital Linz, and Clinical Institute for Cardiovascular and Metabolic Research, Faculty of Medicine, JKU, Linz, Austria (Clodi).
- Medizinische Universität Graz, Klinische Abteilung für Endokrinologie und Diabetologie, Cardiometabolic Trials Unit, Graz, Austria (Sourij).
- Abteilung Innere Medizin I, Gastroenterologie und Hepatologie, Rheumatologie, Endokrinologie und Diabetologie, Klinikum Wels-Grieskirchen, Wels, Austria (Hubner).
- Medizinische Universität Innsbruck, Universitätsklinik für Innere Medizin I, Innsbruck, Austria (Ebenbichler).
Förderung
- Novartis Pharmaceuticals Corporation
Zitieren
APA
Pätzold, D., Vonbank, A., Clodi, M., Sourij, H., Hubner, D., Ebenbichler, C., Fagan, A., Farries, G., Hofstätter, E., Nitzlader, M., Gangl, D., & Adlbrecht, C. (2026). Real-world assessment of adherence to inclisiran dosing schedule and LDL-C reduction in patients with hypercholesterolemia in Austria. Journal of Clinical Lipidology, 20(9), 1921-1932. https://doi.org/10.1016/j.jacl.2026.07.025
Vancouver
Pätzold D, Vonbank A, Clodi M, Sourij H, Hubner D, Ebenbichler C, et al. Real-world assessment of adherence to inclisiran dosing schedule and LDL-C reduction in patients with hypercholesterolemia in Austria. Journal of Clinical Lipidology. 2026;20(9):1921-1932. doi:10.1016/j.jacl.2026.07.025
BibTeX
@article{Ptzold2026,
author = {Pätzold, Dieter and Vonbank, Alexander and Clodi, Martin and Sourij, Harald and Hubner, Dietmar and Ebenbichler, Christoph and Fagan, Ailís and Farries, Gabriella and Hofstätter, Elisabeth and Nitzlader, Markus and Gangl, Doris and Adlbrecht, Christopher},
title = {Real-world assessment of adherence to inclisiran dosing schedule and LDL-C reduction in patients with hypercholesterolemia in Austria},
journal = {Journal of Clinical Lipidology},
year = {2026},
volume = {20},
number = {9},
pages = {1921--1932},
doi = {10.1016/j.jacl.2026.07.025}
}
EUVIMED